| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | David Andes | Q75205210 |
| P2093 | author name string | Craig WA | |
| P921 | main subject | pharmacokinetics | Q323936 |
| pharmacodynamics | Q725307 | ||
| P304 | page(s) | 10-17 | |
| P577 | publication date | 2005-11-01 | |
| P1433 | published in | Clinical Microbiology and Infection | Q15757285 |
| P1476 | title | Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations | |
| P478 | volume | 11 Suppl 6 |
| Q58088798 | A Systematic Approach to the Selection of the Appropriate Avibactam Concentration for Use with Ceftazidime in Broth Microdilution Susceptibility Testing |
| Q34993851 | A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints. |
| Q41077573 | Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model |
| Q38052855 | Antimicrobial resistance in internal medicine wards |
| Q37998436 | Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly? |
| Q38075482 | Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam |
| Q28249617 | Beyond Susceptible and Resistant, Part II: Treatment of Infections Due to Gram-Negative Organisms Producing Extended-Spectrum β-Lactamases |
| Q55514103 | Can the Ceftriaxone Breakpoints Be Increased Without Compromising Patient Outcomes? |
| Q52591821 | Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations. |
| Q34244192 | Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase. |
| Q57789804 | Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa |
| Q38595451 | Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections |
| Q37055016 | Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations |
| Q42566982 | Cephalosporin MIC distribution of extended-spectrum-{beta}-lactamase- and pAmpC-producing Escherichia coli and Klebsiella species |
| Q37291354 | Clinical significance of extended-spectrum beta-lactamases. |
| Q36329228 | Continuous beta-lactam infusion in critically ill patients: the clinical evidence |
| Q46857071 | Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection |
| Q38741453 | Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival. |
| Q42799124 | Detection of extended-spectrum beta-lactamases among Enterobacteriaceae by use of semiautomated microbiology systems and manual detection procedures |
| Q38165138 | Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae |
| Q42000603 | Effects of breakpoint changes on carbapenem susceptibility rates of Enterobacteriaceae: Results from the SENTRY Antimicrobial Surveillance Program, United States, 2008 to 2012 |
| Q40573594 | Evaluation of Aztreonam Dosing Regimens in Patients With Normal and Impaired Renal Function: A Population Pharmacokinetic Modeling and Monte Carlo Simulation Analysis |
| Q51700680 | Evaluation of detection of extended-spectrum beta-lactamases among Escherichia coli and Klebsiella spp. isolates by VITEK 2 AST-N029 compared to the agar dilution and disk diffusion methods. |
| Q38792841 | Examining the Clinical Effectiveness of Non-Carbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae. |
| Q35090146 | Expert systems in clinical microbiology |
| Q51010477 | High rates of susceptibility to ceftazidime among globally prevalent CTX-M-producing Escherichia coli: potential clinical implications of the revised CLSI interpretive criteria. |
| Q40303951 | Impact of Revised Broad-Spectrum Cephalosporin Clinical and Laboratory Standards Institute Breakpoints on Susceptibility in Enterobacteriaceae Producing AmpC β-Lactamase |
| Q50931903 | Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 200 |
| Q39147849 | Integrating forecast probabilities in antibiograms: a way to guide antimicrobial prescriptions more reliably? |
| Q41429331 | Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae testing susceptible to cefepime by reference methods |
| Q41163382 | Mutagenesis of the CTX-M-type ESBL-is MIC-guided treatment according to the new EUCAST recommendations a safe approach? |
| Q36364100 | Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations |
| Q37287753 | Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients. |
| Q90583736 | Population Pharmacokinetic Modelling of Ceftazidime and Avibactam in the Plasma and Epithelial Lining Fluid of Healthy Volunteers |
| Q35840852 | Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment |
| Q38536299 | Recent Updates on the Role of Pharmacokinetics-pharmacodynamics in Antimicrobial Susceptibility Testing as Applied to Clinical Practice |
| Q35913176 | Setting and revising antibacterial susceptibility breakpoints |
| Q64895247 | Simulating moxalactam dosage for extended-spectrum β-lactamase-producing Enterobacteriaceae using blood antimicrobial surveillance network data. |
| Q53311081 | Stepping Off the Resistance Treadmill. |
| Q38528292 | Strategies to reduce curative antibiotic therapy in intensive care units (adult and paediatric). |
| Q46641706 | Superiority of ceftriaxon to cefazolin in a rat model of obstructive jaundice: an experimental study. |
| Q51330567 | The clinical and public health challenge of Gram-negative resistance in Australasia. |
| Q42561118 | Treatment of extended-spectrum Beta-lactamase enterobacteriaceae with cefepime: the dose matters, too. |
| Q90572956 | WCK 5222 (Cefepime/Zidebactam) Pharmacodynamic Target Analysis against Metallo-β-lactamase producing Enterobacteriaceae in the Neutropenic Mouse Pneumonia Model |
| Q88006230 | White Paper: Developing Antimicrobial Drugs for Resistant Pathogens, Narrow-Spectrum Indications, and Unmet Needs |
| Q35995546 | Zinc Finger Nuclease: A New Approach to Overcome Beta-Lactam Antibiotic Resistance |
| Q85520104 | [Extended-spectrum beta-lactamase producing-enterobacteriaceae] |
Search more.